Faulty brain satiety centers and impaired gut hormone function are risk factors for weight gain in T2 diabetes. A simple antidote? Slow down.
Type 2 Diabetes Patients Show No Increased CV Risk with Once-Weekly Exenatide
The extended-release GLP-1 agonist was added to usual care in T2DM patients with and without previous cardiac disease.
Is Metformin Still Top Drug for Type 2 Diabetes?
A new study evaluated the comparative effectiveness and safety of monotherapy and selected metformin-based combinations for type 2 diabetes.
How Much Does GLP-1 RA Impact Glucose, Weight?
Clinical trials have shown that GLP-1 RAs reduce HbA1c and weight in type 2 diabetes, but are these outcomes confounded by concomitant medications?
Risk of Cardiovascular Events with Dulaglutide
A meta-analysis examined the effect of treatment with a GLP-1 receptor agonist on cardiovascular event risk in type 2 diabetes patients.
GLP-1 RA Effectiveness in Asian vs White Patients
Unlike typical Western patients, type 2 diabetes patients in Asia tend to have lower BMIs. Does this mean responses to GLP-1 RAs differ as well?
Comparing Weight Loss with Liraglutide
Does a GLP-1 receptor agonist offer the same weight-loss benefits to different racial subgroups?
Weight Loss Drug Therapy in Type 2 Diabetes
Which GLP-1 receptor agonist induced weight loss in type 2 diabetes patients?
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.
GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
Inflammation in Diabetes: What Role for Glucose-lowering Drugs?
Some key classes of antidiabetes agents could play a dual physiologic role. Find out which ones hold most promise in this at-a-glance summary.